Kuano / News
Earlier research, perspectives and company updates.
Past event
Kuano’s CTO will be presenting at the Lab Futures Forum (run by Automata and Bits in Bio) to discuss our work linking technologies from the world of quantum computing with real-life drug discovery…
Read the update
Kuano is pleased to announce the successful completion of its Innovate UK-funded project “Streamlined and Targeted Design of NOTUM Inhibitors as Colorectal Cancer Drugs”. This work delivered in vivo…
Read the update
Past event
We are pleased to announce that our CTO, David Wright, will be presenting the latest updates on how our platform is using quantum simulation and AI to design better drugs at the Cambridge…
Read the update
David Wright and Georg Schusteritsch talked to Anna Demming of Foresight about the potential for method development and insights from quantum computing to improve drug design, and what will be needed…
Read the update
David is a senior-level R&D leader and drug hunter in the biopharma industry. He has been President of Astellas Engineered Small Molecules US Inc. (formerly Mitobridge Inc.) and Astellas Engineered…
Read the update
Kuano is delighted to welcome Augustin Amour to the company. Gus will collaborate as a consultant, supporting senior management in our enzymatic franchises. Gus has been with GSK for the past 24…
Read the update
Kuano has been recognised as one of Cofinitive’s #21toWatch companies for 2024. The news was covered by the Cambridge Independent and Startups Magazine.
Read the update
It is with great pleasure that we welcome Cat Stace, Executive Vice President of Business Development, to Kuano. Prior to Kuano, Cat was EVP Business Development for Domainex, during which the…
Read the update
Kuano, a drug discovery company combining quantum mechanics with AI to design the next generation of medicines, is pleased to announce the appointment of Dr Ted Witek to their board of directors…
Read the update
We’re excited to have made the shortlist for the Cofinitive #21toWatch award.
Read the update
Past event
Interested in connecting with Kuano at JPM in San Francisco and learning more about how we are delivering the next generation of small-molecule enzyme inhibitors based on advanced quantum simulations…
Read the update
Mercia Ventures sees the vision and ambition of Kuano to redefine drug discovery with quantum and AI. See the reasons why they invested in us here.
Read the update
Kuano has been featured in Business Weekly.
Read the update
Led by Mercia Ventures, investors include ACF Investors, Ascension Ventures, o2h Ventures, Meltwind Advisory LLP and angel investors. Funds will enable further growth and validation of Kuano’s…
Read the update
To celebrate AI Appreciation Day this week, we have been featured on the Oracle for Research blog.
Read the update
Past event
Interested in connecting with Kuano at BIO-Europe Spring in Basel, Switzerland, and learning more about how we are delivering the next generation of small-molecule enzyme inhibitors based on advanced…
Read the update
Podcast interview with David Wright, CTO at Kuano. Hear Dave’s perspective on drug discovery, quantum and AI, and what we’re building at Kuano.
Read the update
Cambridge, UK, 9 January 2023: Kuano Ltd today announces grant funding from Innovate UK for a £540,000 project, “Streamlined and Targeted Design of NOTUM Inhibitors as Colorectal Cancer Drugs”. Bowel…
Read the update
Cambridge, UK, 15 August 2022: Kuano Ltd today announced the appointment of Denise Moody as Chief Operating Officer (COO). Denise Moody brings to Kuano more than 30 years’ experience in the…
Read the update
Antonio is an experienced CEO with a demonstrated history of working in the pharmaceutical industry, including as CEO of Cycle Pharmaceuticals.
Read the update
Kuano is excited to have been able to join the third session of this year’s Computational Health stream of the Creative Destruction Lab (CDL). This is the first year of the new strand in Seattle and…
Read the update
Kuano closes its £1m seed round, led by ACF Investors, o2h Ventures and a syndicate of angel investors based in Cambridge, London and the US.
Read the update
Kuano is an official graduate of the Quantum stream of Creative Destruction Lab (CDL), one of the world’s top deep-tech accelerators.
Read the update
London, UK, 24 June 2021: Kuano Ltd is excited to announce a research collaboration with the Alzheimer’s Research UK University College London Drug Discovery Institute (ARUK UCL DDI). The…
Read the update
London, UK, 24 May 2021: Kuano Ltd is pleased to announce the appointment of Dr Andy Mulvaney to its Board as a Non-Executive Director. Andy is a seasoned industry executive and, in addition to…
Read the update
London, UK, 25 February 2021: Kuano is excited to announce that the o2h human health EIS Fund is leading a consortium of investors participating in a pre-seed round in order to establish proof of…
Read the update
Innovate UK has awarded Kuano a “Business-led innovation in response to global disruption” grant to build a combined AI and modelling service for rapid-response drug design.
Read the update
Kuano has been selected to join the COVID-19 High Performance Computing (HPC) Consortium and will work with AWS to identify novel COVID-19 drugs using a combination of virtual screening and machine…
Read the update
We are excited to have become an SME member of CrowdHelix, an EU and UK-focused community of over 4030 SMEs and research & innovation professionals working together to enable collaborations and…
Read the update
Kuano has joined CompBioMed, a European HPC Centre of Excellence, as an associate partner. CompBioMed brings together leading academic institutions (including UCL, University of Oxford and University…
Read the update